Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar;47(3):245-250.
doi: 10.1111/1346-8138.15195. Epub 2019 Dec 29.

Increased risk of bullous pemphigoid in dipeptidyl peptidase 4 inhibitors: A nationwide, population-based, cohort study in Taiwan

Chih-Tsung Hung  1   2 , Jhih-Syuan Liu  3 , Cheng-Yi Cheng  4 , Chi-Hsiang Chung  5   6 , Chien-Ping Chiang  1 , Wu-Chien Chien  5   7   8 , Wei-Ming Wang  1   2
Affiliations

Increased risk of bullous pemphigoid in dipeptidyl peptidase 4 inhibitors: A nationwide, population-based, cohort study in Taiwan

Chih-Tsung Hung et al. J Dermatol. 2020 Mar.

Abstract

Recent studies revealed the risk of bullous pemphigoid (BP) in patients with diabetes mellitus (DM) taking dipeptidyl peptidase 4 (DPP-4) inhibitors. To clarify the relationship between taking DPP-4 inhibitors and the risk of BP among patients with DM, we conducted a cohort study by using the National Health Insurance Research Database of Taiwan from 1 January 2009 to 31 December 2015. We identified 6340 patients with DM taking DPP-4 inhibitors and 25 360 DM patients who had not taken DPP-4 inhibitors during the 7-year follow-up period. Compared with the non-DPP-4 inhibitor group, patients taking DDP-4 inhibitors had a higher risk of BP (adjusted hazard ratio [aHR], 2.382; 95% confidence interval (CI), 1.163-4.883; P = 0.017]. Among the DPP-4 inhibitors available in Taiwan, vildagliptin showed the highest risk of BP (aHR, 2.849; 95% CI, 1.893-4.215; P < 0.001), followed by saxagliptin (aHR, 2.657; 95% CI, 1.770-3.934; P < 0.001). Subgroup analysis revealed that the higher risk of BP was observed in patients older than 65 years (aHR, 2.403; 95% CI, 1.590-3.627; P < 0.001). This study revealed that treatment with DPP-4 inhibitors, especially vildagliptin, was significantly associated with an increased risk of BP among DM patients.

Keywords: bullous pemphigoid; diabetes mellitus; dipeptidyl peptidase 4 inhibitors; saxagliptin; vildagliptin.

PubMed Disclaimer

References

    1. Genovese G, Di Zenzo G, Cozzani E et al. New insights into the pathogenesis of bullous pemphigoid: 2019 update. Front Immunol 2019; 10: 1506.
    1. Labib RS, Anhalt GJ, Patel HP et al. Molecular heterogeneity of the bullous pemphigoid antigens as detected by immunoblotting. J Immunol 1986; 136: 1231-1235.
    1. Amagai M, Hashimoto T, Tajima S et al. Partial cDNA cloning of the 230-kD mouse bullous pemphigoid antigen by use of a human monoclonal anti-basement membrane zone antibody. J Invest Dermatol 1990; 95: 252-259.
    1. Meyer LJ, Taylor TB, Kadunce DP et al. Two groups of bullous pemphigoid antigens are identified by affinity-purified antibodies. J Invest Dermatol 1990; 94: 611-616.
    1. Schmidt E, Zillikens D. Pemphigoid diseases. Lancet 2013; 381: 320-332.

MeSH terms

LinkOut - more resources